Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of YYD601 vs Nexium in Healthy Adults
NCT03985319Phase 1Completed
- Sponsor
- Yooyoung Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of YYD601 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Yooyoung Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Day 16 and Area Under the Curve at Day 16. Started Jul 2019; status: completed.
02
Drugs
YYD601
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03985319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985319.